RDEA3170 and Allopurinol Combination Study in Gout Subjects

Summary

This is a Phase 1b, randomized, open-label, drug-drug interaction study in adult male subjects with gout. It is designed to assess the pharmacokinetics (PK) and pharmacodynamics (PD) of RDEA3170 or allopurinol alone and in combination in the fed state.

Timeline

Start

2014-11-01

Primary completion

2015-04-06

Completion

2015-09-11

Drugs

Indications